ReHeva Biosciences, an innovative biopharmaceutical startup, is thrilled to announce the successful completion of its Phase I Safety Trial for its groundbreaking drug, RH324. This achievement represents a major milestone in the company's mission to enhance cancer treatment and improve patient care. RH324 is designed to help individuals with cancer live longer and healthier lives, utilizing naturally derived complex drugs.

The Phase I trial was conducted in partnership with Case Comprehensive Cancer Center University Hospitals and Case Western Reserve University in Cleveland, with a focus on evaluating the safety and tolerance of escalating doses of RH324 in patients with advanced non-small cell lung cancer (NSCLC) who did not respond to previous treatments.

ReHeva Biosciences, expressed the company's commitment to revolutionizing cancer treatment. ReHeva's approach harnesses the potential of plant-derived agents to target various tissues and mechanisms of action, contributing to the evolution of cancer treatment.

ReHeva apart from its competitors is its proprietary methods of drug preparation. Founded in 2016 by Dr. Kaul, the company has leveraged over two decades of pre-clinical research and development to establish its position as a leading force in oncology research, with studies published in prestigious peer-reviewed journals.

ReHeva received the FDA Investigational New Drug allowance (IND), paving the way for the Phase I Safety Study for RH324 in advanced NSCLC patients. This is a crucial step toward achieving FDA approval for RH324, which holds the potential to target various pathways involved in cancer progression.

ReHeva's study and Director of the Phase 1 Clinical Trials Program at University Hospitals Seidman Cancer Center, added that partnering with ReHeva could provide patients with a less toxic treatment option for cancer.

The successful completion of the Phase I Safety and Tolerability trial allows for future Phase 2 trials to address multiple cancer types, paving the way for the RH324 clinical program's expansion.

ReHeva Biosciences also emphasizes the significance of partnerships in achieving its mission. A key partnership with 80 Acres Farms, a vertical farming company in Hamilton, Ohio, ensures a consistent and large-scale supply of the botanical raw material required for research. By utilizing controlled-environment agriculture (CEA) technology, 80 Acres Farms can grow crops indoors with precision, free from pesticides, and unaffected by weather and seasons, providing a reliable supply chain for ReHeva's research.

The company is actively exploring educational partnerships with universities like MD Anderson Cancer Center, The Ohio State University, and Emory University, with the aim of conducting additional clinical trials to further establish the effectiveness and safety of botanical-based drugs in treating various conditions, including cancer.

ReHeva Biosciences has secured over $7 million in funding, reflecting its groundbreaking efforts in the field. For more information about ReHeva Biosciences and its transformative work, please visit ReHevaBiosciences.com.

RH324 is an investigational new drug manufactured by ReHeva Biosciences. This botanical drug substance preserves the natural constituents of the plant, including proteins, amino acids, fatty acids, carbohydrates, vitamins, minerals, and phytochemicals. It is being developed in compliance with the FDA Guidance for Industry for Botanical Drug Products.

 

Source: prnewswire.com

Report Abuse